Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.

Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G.

Cancer Treat Rev. 2018 Jun 11;68:102-110. doi: 10.1016/j.ctrv.2018.06.005. [Epub ahead of print] Review.

2.

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A.

Ann Oncol. 2018 Jun 11. doi: 10.1093/annonc/mdy214. [Epub ahead of print]

PMID:
29893790
3.

Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).

Gori S, Puglisi F, Cinquini M, Pappagallo G, Frassoldati A, Biganzoli L, Cortesi L, Fiorentino A, Angiolini C, Tinterri C, De Censi A, Levaggi A, Del Mastro L.

Eur J Cancer. 2018 Aug;99:9-19. doi: 10.1016/j.ejca.2018.04.006. Epub 2018 Jun 7. Review.

PMID:
29886394
4.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group.

N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.

5.

Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.

Iacono D, Cinausero M, Gerratana L, Angione V, Scott CA, De Maglio G, Pizzolitto S, Di Loreto C, Puglisi F, Fasola G, Minisini AM.

Melanoma Res. 2018 May 22. doi: 10.1097/CMR.0000000000000462. [Epub ahead of print]

PMID:
29794562
6.

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Pirosa MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F.

Expert Rev Mol Diagn. 2018 May 3:1-9. doi: 10.1080/14737159.2018.1470929. [Epub ahead of print]

PMID:
29707981
7.

Atezolizumab for the treatment of breast cancer.

Basile D, Pelizzari G, Vitale MG, Lisanti C, Cinausero M, Iacono D, Puglisi F.

Expert Opin Biol Ther. 2018 May;18(5):595-603. doi: 10.1080/14712598.2018.1469619. Epub 2018 May 8.

PMID:
29690797
8.

Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.

Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale MG, Fanotto V, Lisanti C, Mansutti M, Minisini AM, Aprile G, De Laurentiis M, Montemurro F, Del Mastro L, Puglisi F.

Breast. 2018 Aug;40:45-52. doi: 10.1016/j.breast.2018.04.011. Epub 2018 Apr 19.

PMID:
29679936
9.

Triptorelin for Fertility Preservation in Adolescents Treated With Chemotherapy for Cancer.

Meli M, Caruso-Nicoletti M, La Spina M, Nigro LL, Samperi P, D'Amico S, Bellia F, Miraglia V, Licciardello M, Cannata E, Marino S, Cimino C, Puglisi F, Valvo LL, Pezzulla A, Russo G, Di Cataldo A.

J Pediatr Hematol Oncol. 2018 May;40(4):269-276. doi: 10.1097/MPH.0000000000001144.

PMID:
29620680
10.

Reply to the letter "Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association".

Poletto E, Martel S, Lambertini M, Puglisi F.

Breast. 2018 Jun;39:151-152. doi: 10.1016/j.breast.2018.03.003. Epub 2018 Mar 17. No abstract available.

PMID:
29555407
11.

New Insights on Water Buffalo Genomic Diversity and Post-Domestication Migration Routes From Medium Density SNP Chip Data.

Colli L, Milanesi M, Vajana E, Iamartino D, Bomba L, Puglisi F, Del Corvo M, Nicolazzi EL, Ahmed SSE, Herrera JRV, Cruz L, Zhang S, Liang A, Hua G, Yang L, Hao X, Zuo F, Lai SJ, Wang S, Liu R, Gong Y, Mokhber M, Mao Y, Guan F, Vlaic A, Vlaic B, Ramunno L, Cosenza G, Ahmad A, Soysal I, Ünal EÖ, Ketudat-Cairns M, Garcia JF, Utsunomiya YT, Baruselli PS, Amaral MEJ, Parnpai R, Drummond MG, Galbusera P, Burton J, Hoal E, Yusnizar Y, Sumantri C, Moioli B, Valentini A, Stella A, Williams JL, Ajmone-Marsan P.

Front Genet. 2018 Mar 2;9:53. doi: 10.3389/fgene.2018.00053. eCollection 2018.

12.

Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.

Ongaro E, Gerratana L, Cinausero M, Pelizzari G, Poletto E, Giangreco M, Andreetta C, Pizzolitto S, Di Loreto C, Minisini AM, Mansutti M, Russo S, Fasola G, Puglisi F.

Future Oncol. 2018 Apr;14(9):849-859. doi: 10.2217/fon-2017-0384. Epub 2018 Mar 12.

PMID:
29527957
13.

MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.

Gurrieri L, De Carlo E, Gerratana L, De Maglio G, Macerelli M, Pisa FE, Masiero E, Aprile G, Follador A, Puglisi F, Fasola G, Rizzato S, Pizzolitto S.

Future Oncol. 2018 Apr;14(8):699-707. doi: 10.2217/fon-2017-0437. Epub 2018 Mar 9.

PMID:
29521523
14.

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.

De Angelis C, Di Maio M, Crispo A, Giuliano M, Schettini F, Bonotto M, Gerratana L, Iacono D, Cinausero M, Riccardi F, Ciancia G, De Laurentiis M, Puglisi F, De Placido S, Arpino G.

Oncotarget. 2017 Nov 24;8(68):112816-112824. doi: 10.18632/oncotarget.22643. eCollection 2017 Dec 22.

15.

Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.

Caggiari L, Miolo G, Buonadonna A, Basile D, Santeufemia DA, Cossu A, Palmieri G, De Zorzi M, Fornasarig M, Alessandrini L, Canzonieri V, Lo Re G, Puglisi F, Steffan A, Cannizzaro R, De Re V.

Int J Mol Sci. 2017 Dec 23;19(1). pii: E47. doi: 10.3390/ijms19010047.

16.

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.

De Placido S, Giuliano M, Schettini F, Von Arx C, Buono G, Riccardi F, Cianniello D, Caputo R, Puglisi F, Bonotto M, Fabi A, Bilancia D, Ciccarese M, Lorusso V, Michelotti A, Bruzzese D, Veneziani BM, Locci M, De Laurentiis M, Arpino G.

Breast. 2018 Apr;38:86-91. doi: 10.1016/j.breast.2017.12.012. Epub 2018 Jan 4.

PMID:
29287189
17.

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, Montemurro F, Bernardo A, Risi E, Zanardi E, Ziliani S, Mura S, Dellepiane C, Del Mastro L, Minisini AM, Puglisi F.

Breast. 2018 Feb;37:142-147. doi: 10.1016/j.breast.2017.11.004. Epub 2017 Nov 21.

PMID:
29161652
18.

An historical approach to the genetic distribution of KIR and HLA ligands in Eastern Sicilians compared to modern descendants of their invaders.

Capittini C, Messina F, Puglisi F, Azzaro M, Toscano S, De Silvestri A, Tinelli C, Sortino G.

Hum Immunol. 2018 Jan;79(1):5-12. doi: 10.1016/j.humimm.2017.10.008. Epub 2017 Oct 25.

PMID:
29078989
19.

Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.

Basile D, Cinausero M, Iacono D, Pelizzari G, Bonotto M, Vitale MG, Gerratana L, Puglisi F.

Cancer Treat Rev. 2017 Dec;61:15-22. doi: 10.1016/j.ctrv.2017.09.006. Epub 2017 Oct 6. Review.

PMID:
29078133
20.

Determinants of Last-line Treatment in Metastatic Breast Cancer.

Cinausero M, Gerratana L, De Carlo E, Iacono D, Bonotto M, Fanotto V, Buoro V, Basile D, Vitale MG, Rihawi K, Fasola G, Puglisi F.

Clin Breast Cancer. 2018 Jun;18(3):205-213. doi: 10.1016/j.clbc.2017.07.008. Epub 2017 Jul 14.

PMID:
28781022
21.

Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.

Tibullo D, Giallongo C, Puglisi F, Tomassoni D, Camiolo G, Cristaldi M, Brundo MV, Anfuso CD, Lupo G, Stampone T, Li Volti G, Amenta F, Avola R, Bramanti V.

Mol Neurobiol. 2018 Apr;55(4):3344-3350. doi: 10.1007/s12035-017-0575-6. Epub 2017 May 11.

PMID:
28497200
22.

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L.

Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11.

PMID:
28479052
23.

Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.

Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V.

Breast Cancer Res Treat. 2017 Jun;163(3):637. doi: 10.1007/s10549-017-4219-3. No abstract available.

PMID:
28374322
24.

Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.

Lorusso V, Cinieri S, Latorre A, Porcu L, Del Mastro L, Puglisi F, Barni S.

Future Oncol. 2017 May;13(11):971-978. doi: 10.2217/fon-2016-0530. Epub 2017 Feb 24.

PMID:
28326833
25.

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.

Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V.

Breast Cancer Res Treat. 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Erratum in: Breast Cancer Res Treat. 2017 Jun;163(3):637.

PMID:
28289852
26.

HLA-A, -B and -C genotyping and haplotype frequencies in a population of 50 healthy unrelated Bone Marrow donors from Eastern Sicily.

Capittini C, De Silvestri A, Puglisi F, Azzaro M, Toscano S, Rendine S, Tinelli C, Sortino G.

Hum Immunol. 2017 Apr;78(4):323-324. doi: 10.1016/j.humimm.2017.01.010. Epub 2017 Feb 3. No abstract available.

PMID:
28167235
27.

Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.

Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F.

Expert Opin Biol Ther. 2017 Mar;17(3):365-374. doi: 10.1080/14712598.2017.1282944. Epub 2017 Jan 30. Review.

PMID:
28092723
28.

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.

Cesaratto L, Grisard E, Coan M, Zandonà L, De Mattia E, Poletto E, Cecchin E, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, Spizzo R.

Cell Death Dis. 2016 Dec 22;7(12):e2526. doi: 10.1038/cddis.2016.448. No abstract available.

29.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

PMID:
27951450
30.

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.

Cesaratto L, Grisard E, Coan M, Zandonà L, De Mattia E, Poletto E, Cecchin E, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, Spizzo R.

Cell Death Dis. 2016 Sep 22;7(9):e2374. doi: 10.1038/cddis.2016.278. Erratum in: Cell Death Dis. 2016 Dec 22;7(12 ):e2526.

31.

Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.

Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F.

Breast. 2017 Feb;31:114-120. doi: 10.1016/j.breast.2016.10.021. Epub 2016 Nov 9.

32.

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.

Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, Poggio F, Bonotto M, Floris G, Van Asten K, Wildiers H, Neven P, de Azambuja E, Paesmans M, Azim HA Jr.

Br J Cancer. 2016 Dec 6;115(12):1471-1478. doi: 10.1038/bjc.2016.359. Epub 2016 Nov 1.

33.

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G.

Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8.

PMID:
27502725
34.

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM).

Tibullo D, Caporarello N, Giallongo C, Anfuso CD, Genovese C, Arlotta C, Puglisi F, Parrinello NL, Bramanti V, Romano A, Lupo G, Toscano V, Avola R, Brundo MV, Di Raimondo F, Raccuia SA.

Nutrients. 2016 Oct 1;8(10). pii: E611.

35.

Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example.

Gerratana L, De Maglio G, De Pellegrin A, Follador A, Rihawi K, Pizzolitto S, Puglisi F, Fasola G.

Onco Targets Ther. 2016 Aug 30;9:5399-404. doi: 10.2147/OTT.S104748. eCollection 2016.

36.

Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy.

Puglisi F, Agostinetto E, Gerratana L, Bozza C, Cancian M, Iannelli E, Ratti G, Cinieri S, Numico G.

Future Oncol. 2017 Feb;13(3):233-248. doi: 10.2217/fon-2016-0383. Epub 2016 Sep 12.

37.

Conformational modulation mediated by polyglutamine expansion in CAG repeat expansion disease-associated proteins.

Verani M, Bustamante M, Martufi P, Daldin M, Cariulo C, Azzollini L, Fodale V, Puglisi F, Weiss A, Macdonald D, Petricca L, Caricasole A.

Biochem Biophys Res Commun. 2016 Sep 16;478(2):949-55. doi: 10.1016/j.bbrc.2016.08.057. Epub 2016 Aug 9.

PMID:
27520369
38.

A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.

Puglisi F, Bisagni G, Ciccarese M, Fontanella C, Gamucci T, Leo L, Molino A, Silva RR, Marchetti P.

Future Oncol. 2016 Nov;12(22):2589-2602. doi: 10.2217/fon-2016-0295. Epub 2016 Jul 22.

PMID:
27443691
39.

Do platinum salts fit all triple negative breast cancers?

Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F.

Cancer Treat Rev. 2016 Jul;48:34-41. doi: 10.1016/j.ctrv.2016.06.004. Epub 2016 Jun 11. Review.

PMID:
27343437
40.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A.

J Clin Oncol. 2016 Oct 1;34(28):3400-8. doi: 10.1200/JCO.2015.65.6595. Epub 2016 Jun 20.

41.

Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?

Fontanella C, De Carlo E, Cinausero M, Pelizzari G, Venuti I, Puglisi F.

Cancer Treat Rev. 2016 May;46:80-8. doi: 10.1016/j.ctrv.2016.03.014. Epub 2016 Apr 1. Review.

PMID:
27218867
42.

Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J.

Br J Cancer. 2016 Apr 26;114(9):956-64. doi: 10.1038/bjc.2016.71. Epub 2016 Apr 19.

43.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perelló A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF.

J Clin Oncol. 2016 May 10;34(14):1601-10. doi: 10.1200/JCO.2015.64.8675. Epub 2016 Mar 28.

44.

In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.

Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, Cesselli D.

Breast Cancer Res. 2016 Mar 9;18(1):30. doi: 10.1186/s13058-016-0687-3.

45.

Long-acting insulin analog detemir displays reduced effects on adipocyte differentiation of human subcutaneous and visceral adipose stem cells.

Cignarelli A, Perrini S, Nigro P, Ficarella R, Barbaro M, Peschechera A, Porro S, Natalicchio A, Laviola L, Puglisi F, Giorgino F.

Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):333-44. doi: 10.1016/j.numecd.2015.11.010. Epub 2015 Nov 30.

PMID:
26947594
46.

Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice.

Martella G, Madeo G, Maltese M, Vanni V, Puglisi F, Ferraro E, Schirinzi T, Valente EM, Bonanni L, Shen J, Mandolesi G, Mercuri NB, Bonsi P, Pisani A.

Neurobiol Dis. 2016 Jul;91:21-36. doi: 10.1016/j.nbd.2015.12.020. Epub 2016 Feb 23.

PMID:
26916954
47.

Translational and clinical research highlights from the 38th San Antonio Breast Cancer Symposium.

Fontanella C, Puglisi F.

Future Oncol. 2016;12(8):1005-8. doi: 10.2217/fon-2016-0021. Epub 2016 Feb 9.

48.

Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review.

Puglisi F, Rea D, Kroes MA, Pronzato P.

Cancer Treat Rev. 2016 Feb;43:36-49. doi: 10.1016/j.ctrv.2015.11.012. Epub 2015 Dec 8. Review.

PMID:
26827691
49.

[Complementary and alternative medicine in oncology].

Bozza C, Agostinetto E, Gerratana L, Puglisi F.

Recenti Prog Med. 2015 Dec;106(12):601-7. doi: 10.1701/2094.22648. Review. Italian.

PMID:
26780069
50.

Hepatitis B and cancer: A practical guide for the oncologist.

Bozza C, Cinausero M, Iacono D, Puglisi F.

Crit Rev Oncol Hematol. 2016 Feb;98:137-46. doi: 10.1016/j.critrevonc.2015.10.017. Epub 2015 Nov 6. Review.

Supplemental Content

Loading ...
Support Center